Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Abroad (travel likely)RecruitingPHASE2, PHASE3
Conditions
Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale University, New Haven, Connecticut, United States
Children's National Medical Center, Washington D.C., District of Columbia, United States
Nemours Children's Health, Jacksonville, Florida, United States
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Royal London Hospital, London, United Kingdom
Royal Manchester Children's Hospital, Manchester, United Kingdom
Study leads
Calcilytix Medical Director
Study Director
Calcilytix Therapeutics, Inc., a BridgeBio company